Problem of mild bronchial asthma revisited
https://doi.org/10.21518/2079-701X-2019-12-70-77
Abstract
It is estimated that 50-75% of bronchial asthma cases have mild (intermittent or persistent) severity of asthma. Despite the minimal number of daily symptoms, endobronchial inflammation and a high risk of exacerbations have been demonstrated in a significant proportion of patients. According to the current guidelines, anti-inflammatory drugs - inhaled glucocorticosteroids - maintenance therapy is only added at stage 1, which is characterized by an insufficient level of control and repeated exacerbations due to the use of short-acting в-agonists to be taken as required. Inhaled glucocorticosteroids in low doses become the drugs of choice at stage 2 for patients with mild persistent bronchial asthma. As-needed use of inhaled glucocorticosteroids combined with в-agonists, which has a rapid onset of action (salbutamol or formoterol) may become an alternative to the daily used of drugs. The choice of such type of management should be justified by the low risk of exacerbation (based on an assessment of risk factors for adverse clinical out-comes/exacerbations of bronchial asthma). The as-needed use of such combination can provide a high patient commitment to medical recommendations, create a sufficient anti-inflammatory effect, reduce the likelihood of exacerbations and reduce the risk of adverse effects.
About the Authors
Y. G. Belotserkovskaya
Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuous Professional Education» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Belotserkovskaya Yuliya Gennad'evna - Cand. of Sci. (Med.), Associate Professor, Chair for Pulmonology.
125993, Moscow, Barrikadnaya St., 2/1, Bldg. 1
A. I. Sinopalnikov
Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuous Professional Education» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Sinopal'nikov Aleksandr Irogevich - Dr. of Sci. (Med.), Professor, Deputy Head of Chair for Pulmonology.
125993, Moscow, Barrikadnaya St., 2/1, Bldg. 1
A. G. Romanovskikh
Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuous Professional Education» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Romanovskikh Anna Gennad'evna - Cand. of Sci. (Med.), Associate Professor, Chair for Pulmonology.
125993, Moscow, Barrikadnaya St., 2/1, Bldg. 1
I. P. Smirnov
Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuous Professional Education» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Smirnov Igor Pavlovich - Teaching Assistant - Chair for Pulmonology.
125993, Moscow, Barrikadnaya St., 2/1, Bldg. 1
References
1. MasoLi M., Fabian D., HoLt S., Beasley R. Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary ofthe GINA Dissemination Committee report. Allergy. 2004;(59):469-478.
2. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of DiseaseStudy 2015. LancetRespirMed. 2017;(5):691-706.
3. Braido F., Brusselle G., Guastalla D., et al. Determinants and impact of suboptimal asthma control in Europe: the international crosssectional and longitudinal assessment on asthma control (LIAISON) study. Respir Res. 2016;(17):51.
4. Dusser D., Montani D., Chanez P, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy. 2007;(62):591-604.
5. Olaguibel J.M., Ouirce S., Julia B., et al. Measurement ofasthma control according to Global Initiative for Asthmaguidelines: a comparison with the Asthma Control Ouestionnaire. Respir Res. 2012;(13):50.
6. Price D., Fletcher M., vander Molen T. Asthma control and management in 8,000 Europe an patients: the REcognise Asthma and LInkto Symptoms and Experience (REALISE) survey. NPJPrimCareRespirMed. 2014;(24):14009.
7. GINA 2018. Режим доступа: https://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-V1.3-002.pdf.
8. National Heart, Lung and Blood Institute, National Asthma Education and Prevention Program. Expert panel report 3: guidelines for the diagnosis and management of asthma. Full report 2007. Available at: http://www.sciencedi-rect.com/science/article/pii/S0091674907018234?via%3Dihub.
9. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax. 2014;69(Suppl 1):1-192.
10. Chinese Medical Association of respiratory disease branch Asthma Study Group. [The Chinese guideline for asthma management and prevention]. Zhonghua Jie He He Hu Xi Za Zhi. 2016;39(9):675-697. doi: https://doi.org/10.3760/cma.j.issn.1001-0939.2016.09.007.Chinese.
11. GEMA. 2009 (Spanish guideline on the management of asthma). J Investig Allergol Clin Immunol. 2010;20(Suppl 1):1-59.
12. Ichinose M., Sugiura H., Nagase H., Yamaguchi M., Inoue H., Sagara H., et al. Japanese guidelines for adult asthma 2017. Allergol Int. 2017;66(2):163-89.
13. Stempel D.A., Stoloff S.W., CarranzaRosenzweig J.R., Stanford R.H., Ryskina K.L., Legorreta A.P Adherence to asthma controller medication regimens. Respir Med. 2005;99(10):1263-7.
14. Suissa S., Ernst P, Benayoun S., Baltzan M., Cai B. Low-doseinhaledcorticosteroidsandthepreve ntionofdeathfromasthma. N. Engl. J. Med. 2000;343(5):332-6.
15. Cates CJ., Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid main-tenance), for chronic asthma in adults and children. Cochrane Database of Systematic Reviews. 2013;(Issue 4). Art. No.: CD007313.
16. Kew K.M., Karner C., Mindus S.M., Ferrara G. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database of Systematic Reviews. 2013Dec 16;(12):CD009019. doi: 10.1002/14651858.CD009019.pub2.
17. Papi A., Corradi M., Pigeon-Francisco C. et al. Beclometasone-formoterol as maintenance and relievertreatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir Med. 2013Mar;1(1):23-31.
18. Patel M., Pilcher J., Pritchard A. et al. SMART Study Group. Efficacy and safety of maintenance andreliever combination budesonide-formoterol inhaler in patients with asthma at risk of sever-eexacerbations: a randomised controlled trial. LancetRespirMed. 2013 Mar;1(1):32-42.
19. Suissa S., Ernst P. Inhaledcorticosteroids: impactonasthmamorbidityandmortality. J Allergy Clin Immunol. 2001;(107):937-944.
20. Adams N.P, Bestall J.B., Malouf R. et al. Inhaled beclomethasone versusplacebo for chronic asthma. Cochrane Database Syst Rev. 2005;(1):CD002 738.
21. Barnes PJ. Inhaledcorticosteroids. Pharmaceuticals (Basel). 2010;(3):514-540.
22. Wang G., Zhang X., Zhang H.P et al. Corticosteroid plus (32-agonist in a single inhaler as reliever therapy in intermittent and mild asthma: a proof-of-concept systematic review and meta-analysis. Respiratory Research. 2017;(18):203.
23. Haahtela T., Tamminen K., Malmberg L.P, Zetterstrom O., Karjalainen J., Yla-Outinen H. et al. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: a SOMA study. Eur Respir J. 2006;28(4):748-55.
24. Papi A., Canonica G.W., Maestrelli P, Paggiaro P, Olivieri D., Pozzi E. et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007;356(20):2040-52.
25. Papi A., Nicolini G., Baraldi E., Boner A.L., Cutrera R., Rossi G.A. et al. Regular vs prn nebulized treatment in wheeze preschool children. Allergy. 2009;64(10):1463-71.
26. Martinez F.D., Chinchilli V.M., Morgan WJ., Boehmer SJ., Lemanske R.F., Mauger D.T. et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2011;377(9766):650-7.
27. Lazarinis N., Jorgensen L., Ekstrom T., Bjermer L., Dahlen B., Pullerits T. et al. Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction. Thorax. 2014;69(2):130-6.
28. Fitzpatrick A.M., Jackson DJ., Mauger D.T., Boehmer SJ., Phipatanakul W., Sheehan WJ. et al. Individualized therapy for persistent asthma in youngchildren. J Allergy Clin Immunol. 2016;(21):21.
Review
For citations:
Belotserkovskaya YG, Sinopalnikov AI, Romanovskikh AG, Smirnov IP. Problem of mild bronchial asthma revisited. Meditsinskiy sovet = Medical Council. 2019;(12):70-77. (In Russ.) https://doi.org/10.21518/2079-701X-2019-12-70-77
Views:
636
Email this article 